http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 07 May 2025 15:56:55 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Investing/Charles+River+to+initiate+a+review+amid+Elliott+stake+-+Is+a+sale+next%3F/24757251.html <p dir="ltr">Investing.com -- Charles River Laboratories (NYSE:CRL) announced Wednesday it will appoint four new directors to its board and launch a comprehensive strategic review following a cooperation agreement with activist hedge fund Elliott Investment Management, the company’s largest shareholder. The changes will be overseen by a newly formed Strategic Planning and Capital Allocation Committee aimed at enhancing long-term shareholder value.</p><p dir="ltr">The move comes amid increased pressure on Charles River following a steep decline in its stock price and an FDA announcement of the “phasing-out” of animal testing requirements in preclinical research. Sources familiar with the agreement told Investing.com that Elliott http://www.streetinsider.com/Investing/Charles+River+to+initiate+a+review+amid+Elliott+stake+-+Is+a+sale+next%3F/24757251.html Wed, 07 May 2025 15:56:55 -0400 CAH CRL CTLT SYNH TMO http://www.streetinsider.com/Investing/Charles+River+to+initiate+a+review+amid+Elliott+stake+-+Is+a+sale+next%3F/24757251.html <p dir="ltr">Investing.com -- Charles River Laboratories (NYSE:CRL) announced Wednesday it will appoint four new directors to its board and launch a comprehensive strategic review following a cooperation agreement with activist hedge fund Elliott Investment Management, the company’s largest shareholder. The changes will be overseen by a newly formed Strategic Planning and Capital Allocation Committee aimed at enhancing long-term shareholder value.</p><p dir="ltr">The move comes amid increased pressure on Charles River following a steep decline in its stock price and an FDA announcement of the “phasing-out” of animal testing requirements in preclinical research. Sources familiar with the agreement told Investing.com that Elliott http://www.streetinsider.com/Investing/Charles+River+to+initiate+a+review+amid+Elliott+stake+-+Is+a+sale+next%3F/24757251.html Wed, 07 May 2025 15:56:55 -0400 CAH CRL CTLT SYNH TMO http://www.streetinsider.com/Investing/Charles+River+to+initiate+a+review+amid+Elliott+stake+-+Is+a+sale+next%3F/24757251.html <p dir="ltr">Investing.com -- Charles River Laboratories (NYSE:CRL) announced Wednesday it will appoint four new directors to its board and launch a comprehensive strategic review following a cooperation agreement with activist hedge fund Elliott Investment Management, the company’s largest shareholder. The changes will be overseen by a newly formed Strategic Planning and Capital Allocation Committee aimed at enhancing long-term shareholder value.</p><p dir="ltr">The move comes amid increased pressure on Charles River following a steep decline in its stock price and an FDA announcement of the “phasing-out” of animal testing requirements in preclinical research. Sources familiar with the agreement told Investing.com that Elliott http://www.streetinsider.com/Investing/Charles+River+to+initiate+a+review+amid+Elliott+stake+-+Is+a+sale+next%3F/24757251.html Wed, 07 May 2025 15:56:55 -0400 CAH CRL CTLT SYNH TMO http://www.streetinsider.com/Investing/Charles+River+to+initiate+a+review+amid+Elliott+stake+-+Is+a+sale+next%3F/24757251.html <p dir="ltr">Investing.com -- Charles River Laboratories (NYSE:CRL) announced Wednesday it will appoint four new directors to its board and launch a comprehensive strategic review following a cooperation agreement with activist hedge fund Elliott Investment Management, the company’s largest shareholder. The changes will be overseen by a newly formed Strategic Planning and Capital Allocation Committee aimed at enhancing long-term shareholder value.</p><p dir="ltr">The move comes amid increased pressure on Charles River following a steep decline in its stock price and an FDA announcement of the “phasing-out” of animal testing requirements in preclinical research. Sources familiar with the agreement told Investing.com that Elliott http://www.streetinsider.com/Investing/Charles+River+to+initiate+a+review+amid+Elliott+stake+-+Is+a+sale+next%3F/24757251.html Wed, 07 May 2025 15:56:55 -0400 CAH CRL CTLT SYNH TMO http://www.streetinsider.com/Investing/Charles+River+to+initiate+a+review+amid+Elliott+stake+-+Is+a+sale+next%3F/24757251.html <p dir="ltr">Investing.com -- Charles River Laboratories (NYSE:CRL) announced Wednesday it will appoint four new directors to its board and launch a comprehensive strategic review following a cooperation agreement with activist hedge fund Elliott Investment Management, the company’s largest shareholder. The changes will be overseen by a newly formed Strategic Planning and Capital Allocation Committee aimed at enhancing long-term shareholder value.</p><p dir="ltr">The move comes amid increased pressure on Charles River following a steep decline in its stock price and an FDA announcement of the “phasing-out” of animal testing requirements in preclinical research. Sources familiar with the agreement told Investing.com that Elliott http://www.streetinsider.com/Investing/Charles+River+to+initiate+a+review+amid+Elliott+stake+-+Is+a+sale+next%3F/24757251.html Wed, 07 May 2025 15:56:55 -0400 CAH CRL CTLT SYNH TMO http://www.streetinsider.com/Investing/BofA+cuts+Novo+Nordisk+shares+target+on+expected+Q1+earnings+miss/24563240.html <p>Investing.com -- Bank of America (BofA) on Friday lowered its price target for <span itemscope itemtype="http://schema.org/Corporation"><span itemprop="name"> Novo Nordisk </span></span> (CSE:NOVOb)k (NYSE:NVO) shares, cautioning that the company may miss its first-quarter earnings projections as sales of its megahit drugs Wegovy and Ozempic, lag.</p> <p>BofA analysts expect Novo Nordisk's first-quarter sales to reach 77 billion Danish kroner (DKK), a 17% year-over-year increase, and earnings before interest and taxes (EBIT) to hit DKK 36 billion, up 14% from the previous year. These figures are approximately 1-2% below the Visible Alpha consensus.</p> <p>The analysts have identified several key factors that could contribute to a potential http://www.streetinsider.com/Investing/BofA+cuts+Novo+Nordisk+shares+target+on+expected+Q1+earnings+miss/24563240.html Fri, 28 Mar 2025 09:47:33 -0400 CTLT NVO http://www.streetinsider.com/Investing/BofA+cuts+Novo+Nordisk+shares+target+on+expected+Q1+earnings+miss/24563240.html <p>Investing.com -- Bank of America (BofA) on Friday lowered its price target for <span itemscope itemtype="http://schema.org/Corporation"><span itemprop="name"> Novo Nordisk </span></span> (CSE:NOVOb)k (NYSE:NVO) shares, cautioning that the company may miss its first-quarter earnings projections as sales of its megahit drugs Wegovy and Ozempic, lag.</p> <p>BofA analysts expect Novo Nordisk's first-quarter sales to reach 77 billion Danish kroner (DKK), a 17% year-over-year increase, and earnings before interest and taxes (EBIT) to hit DKK 36 billion, up 14% from the previous year. These figures are approximately 1-2% below the Visible Alpha consensus.</p> <p>The analysts have identified several key factors that could contribute to a potential http://www.streetinsider.com/Investing/BofA+cuts+Novo+Nordisk+shares+target+on+expected+Q1+earnings+miss/24563240.html Fri, 28 Mar 2025 09:47:33 -0400 CTLT NVO http://www.streetinsider.com/General+News/BofA+cuts+Novo+Nordisk+shares+target+on+expected+Q1+earnings+miss/24563240.html <p>Investing.com -- Bank of America (BofA) on Friday lowered its price target for <span itemscope itemtype="http://schema.org/Corporation"><span itemprop="name"> Novo Nordisk </span></span> (CSE:NOVOb)k (NYSE:NVO) shares, cautioning that the company may miss its first-quarter earnings projections as sales of its megahit drugs Wegovy and Ozempic, lag.</p> <p>BofA analysts expect Novo Nordisk's first-quarter sales to reach 77 billion Danish kroner (DKK), a 17% year-over-year increase, and earnings before interest and taxes (EBIT) to hit DKK 36 billion, up 14% from the previous year. These figures are approximately 1-2% below the Visible Alpha consensus.</p> <p>The analysts have identified several key factors that could contribute to a potential http://www.streetinsider.com/General+News/BofA+cuts+Novo+Nordisk+shares+target+on+expected+Q1+earnings+miss/24563240.html Fri, 28 Mar 2025 09:47:33 -0400 CTLT NVO http://www.streetinsider.com/General+News/BofA+cuts+Novo+Nordisk+shares+target+on+expected+Q1+earnings+miss/24563240.html <p>Investing.com -- Bank of America (BofA) on Friday lowered its price target for <span itemscope itemtype="http://schema.org/Corporation"><span itemprop="name"> Novo Nordisk </span></span> (CSE:NOVOb)k (NYSE:NVO) shares, cautioning that the company may miss its first-quarter earnings projections as sales of its megahit drugs Wegovy and Ozempic, lag.</p> <p>BofA analysts expect Novo Nordisk's first-quarter sales to reach 77 billion Danish kroner (DKK), a 17% year-over-year increase, and earnings before interest and taxes (EBIT) to hit DKK 36 billion, up 14% from the previous year. These figures are approximately 1-2% below the Visible Alpha consensus.</p> <p>The analysts have identified several key factors that could contribute to a potential http://www.streetinsider.com/General+News/BofA+cuts+Novo+Nordisk+shares+target+on+expected+Q1+earnings+miss/24563240.html Fri, 28 Mar 2025 09:47:33 -0400 CTLT NVO http://www.streetinsider.com/Press+Releases/Catalent+Announces+New+Board+Appointments/24376664.html <p class="bwalignc"> <i>Adds three new directors with deep expertise across biopharma and life sciences</i> </p> <p> SOMERSET, N.J.--(BUSINESS WIRE)-- Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings’ ownership. </p><p> Alessandro Maselli, President and CEO, and Board member of Catalent, said “I am excited to work closely with these new Board members as we drive continued growth as an independent CDMO delivering unparalleled service to our pharma and biotech http://www.streetinsider.com/Press+Releases/Catalent+Announces+New+Board+Appointments/24376664.html Thu, 20 Feb 2025 09:00:00 -0400 A.00556501 A.07261051 A.17530805 A.18872811 A.21426713 A.21752794 A.27886773 A.29465233 A.30990768 A.31757664 A.50200199 A.50202556 CTLT H1ZN34 O.00000865 O.00222301 O.00222524 O.00384685 O.00412985 O.00573644 O.00647606 O.02041199 O.02048399 O.05063681 O.22555989 O.26772469 O.55342982 http://www.streetinsider.com/Press+Releases/Catalent+Announces+New+Board+Appointments/24376664.html <p class="bwalignc"> <i>Adds three new directors with deep expertise across biopharma and life sciences</i> </p> <p> SOMERSET, N.J.--(BUSINESS WIRE)-- Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings’ ownership. </p><p> Alessandro Maselli, President and CEO, and Board member of Catalent, said “I am excited to work closely with these new Board members as we drive continued growth as an independent CDMO delivering unparalleled service to our pharma and biotech http://www.streetinsider.com/Press+Releases/Catalent+Announces+New+Board+Appointments/24376664.html Thu, 20 Feb 2025 09:00:00 -0400 A.00556501 A.07261051 A.17530805 A.18872811 A.21426713 A.21752794 A.27886773 A.29465233 A.30990768 A.31757664 A.50200199 A.50202556 CTLT H1ZN34 O.00000865 O.00222301 O.00222524 O.00384685 O.00412985 O.00573644 O.00647606 O.02041199 O.02048399 O.05063681 O.22555989 O.26772469 O.55342982 http://www.streetinsider.com/Press+Releases/Catalent+Announces+New+Board+Appointments/24376664.html <p class="bwalignc"> <i>Adds three new directors with deep expertise across biopharma and life sciences</i> </p> <p> SOMERSET, N.J.--(BUSINESS WIRE)-- Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings’ ownership. </p><p> Alessandro Maselli, President and CEO, and Board member of Catalent, said “I am excited to work closely with these new Board members as we drive continued growth as an independent CDMO delivering unparalleled service to our pharma and biotech http://www.streetinsider.com/Press+Releases/Catalent+Announces+New+Board+Appointments/24376664.html Thu, 20 Feb 2025 09:00:00 -0400 A.00556501 A.07261051 A.17530805 A.18872811 A.21426713 A.21752794 A.27886773 A.29465233 A.30990768 A.31757664 A.50200199 A.50202556 CTLT H1ZN34 O.00000865 O.00222301 O.00222524 O.00384685 O.00412985 O.00573644 O.00647606 O.02041199 O.02048399 O.05063681 O.22555989 O.26772469 O.55342982 http://www.streetinsider.com/Press+Releases/Catalent+Announces+New+Board+Appointments/24376664.html <p class="bwalignc"> <i>Adds three new directors with deep expertise across biopharma and life sciences</i> </p> <p> SOMERSET, N.J.--(BUSINESS WIRE)-- Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings’ ownership. </p><p> Alessandro Maselli, President and CEO, and Board member of Catalent, said “I am excited to work closely with these new Board members as we drive continued growth as an independent CDMO delivering unparalleled service to our pharma and biotech http://www.streetinsider.com/Press+Releases/Catalent+Announces+New+Board+Appointments/24376664.html Thu, 20 Feb 2025 09:00:00 -0400 A.00556501 A.07261051 A.17530805 A.18872811 A.21426713 A.21752794 A.27886773 A.29465233 A.30990768 A.31757664 A.50200199 A.50202556 CTLT H1ZN34 O.00000865 O.00222301 O.00222524 O.00384685 O.00412985 O.00573644 O.00647606 O.02041199 O.02048399 O.05063681 O.22555989 O.26772469 O.55342982 http://www.streetinsider.com/Press+Releases/Catalent+Announces+New+Board+Appointments/24376664.html <p class="bwalignc"> <i>Adds three new directors with deep expertise across biopharma and life sciences</i> </p> <p> SOMERSET, N.J.--(BUSINESS WIRE)-- Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings’ ownership. </p><p> Alessandro Maselli, President and CEO, and Board member of Catalent, said “I am excited to work closely with these new Board members as we drive continued growth as an independent CDMO delivering unparalleled service to our pharma and biotech http://www.streetinsider.com/Press+Releases/Catalent+Announces+New+Board+Appointments/24376664.html Thu, 20 Feb 2025 09:00:00 -0400 A.00556501 A.07261051 A.17530805 A.18872811 A.21426713 A.21752794 A.27886773 A.29465233 A.30990768 A.31757664 A.50200199 A.50202556 CTLT H1ZN34 O.00000865 O.00222301 O.00222524 O.00384685 O.00412985 O.00573644 O.00647606 O.02041199 O.02048399 O.05063681 O.22555989 O.26772469 O.55342982 http://www.streetinsider.com/Press+Releases/Catalent+Announces+New+Board+Appointments/24376664.html <p class="bwalignc"> <i>Adds three new directors with deep expertise across biopharma and life sciences</i> </p> <p> SOMERSET, N.J.--(BUSINESS WIRE)-- Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings’ ownership. </p><p> Alessandro Maselli, President and CEO, and Board member of Catalent, said “I am excited to work closely with these new Board members as we drive continued growth as an independent CDMO delivering unparalleled service to our pharma and biotech http://www.streetinsider.com/Press+Releases/Catalent+Announces+New+Board+Appointments/24376664.html Thu, 20 Feb 2025 09:00:00 -0400 A.00556501 A.07261051 A.17530805 A.18872811 A.21426713 A.21752794 A.27886773 A.29465233 A.30990768 A.31757664 A.50200199 A.50202556 CTLT H1ZN34 O.00000865 O.00222301 O.00222524 O.00384685 O.00412985 O.00573644 O.00647606 O.02041199 O.02048399 O.05063681 O.22555989 O.26772469 O.55342982 http://www.streetinsider.com/Press+Releases/Catalent+Announces+New+Board+Appointments/24376664.html <p class="bwalignc"> <i>Adds three new directors with deep expertise across biopharma and life sciences</i> </p> <p> SOMERSET, N.J.--(BUSINESS WIRE)-- Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings’ ownership. </p><p> Alessandro Maselli, President and CEO, and Board member of Catalent, said “I am excited to work closely with these new Board members as we drive continued growth as an independent CDMO delivering unparalleled service to our pharma and biotech http://www.streetinsider.com/Press+Releases/Catalent+Announces+New+Board+Appointments/24376664.html Thu, 20 Feb 2025 09:00:00 -0400 A.00556501 A.07261051 A.17530805 A.18872811 A.21426713 A.21752794 A.27886773 A.29465233 A.30990768 A.31757664 A.50200199 A.50202556 CTLT H1ZN34 O.00000865 O.00222301 O.00222524 O.00384685 O.00412985 O.00573644 O.00647606 O.02041199 O.02048399 O.05063681 O.22555989 O.26772469 O.55342982 http://www.streetinsider.com/Press+Releases/Catalent+Announces+New+Board+Appointments/24376664.html <p class="bwalignc"> <i>Adds three new directors with deep expertise across biopharma and life sciences</i> </p> <p> SOMERSET, N.J.--(BUSINESS WIRE)-- Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings’ ownership. </p><p> Alessandro Maselli, President and CEO, and Board member of Catalent, said “I am excited to work closely with these new Board members as we drive continued growth as an independent CDMO delivering unparalleled service to our pharma and biotech http://www.streetinsider.com/Press+Releases/Catalent+Announces+New+Board+Appointments/24376664.html Thu, 20 Feb 2025 09:00:00 -0400 A.00556501 A.07261051 A.17530805 A.18872811 A.21426713 A.21752794 A.27886773 A.29465233 A.30990768 A.31757664 A.50200199 A.50202556 CTLT H1ZN34 O.00000865 O.00222301 O.00222524 O.00384685 O.00412985 O.00573644 O.00647606 O.02041199 O.02048399 O.05063681 O.22555989 O.26772469 O.55342982 http://www.streetinsider.com/Press+Releases/Catalent+Announces+New+Board+Appointments/24376664.html <p class="bwalignc"> <i>Adds three new directors with deep expertise across biopharma and life sciences</i> </p> <p> SOMERSET, N.J.--(BUSINESS WIRE)-- Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings’ ownership. </p><p> Alessandro Maselli, President and CEO, and Board member of Catalent, said “I am excited to work closely with these new Board members as we drive continued growth as an independent CDMO delivering unparalleled service to our pharma and biotech http://www.streetinsider.com/Press+Releases/Catalent+Announces+New+Board+Appointments/24376664.html Thu, 20 Feb 2025 09:00:00 -0400 A.00556501 A.07261051 A.17530805 A.18872811 A.21426713 A.21752794 A.27886773 A.29465233 A.30990768 A.31757664 A.50200199 A.50202556 CTLT H1ZN34 O.00000865 O.00222301 O.00222524 O.00384685 O.00412985 O.00573644 O.00647606 O.02041199 O.02048399 O.05063681 O.22555989 O.26772469 O.55342982 http://www.streetinsider.com/Press+Releases/Catalent+Announces+New+Board+Appointments/24376664.html <p class="bwalignc"> <i>Adds three new directors with deep expertise across biopharma and life sciences</i> </p> <p> SOMERSET, N.J.--(BUSINESS WIRE)-- Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings’ ownership. </p><p> Alessandro Maselli, President and CEO, and Board member of Catalent, said “I am excited to work closely with these new Board members as we drive continued growth as an independent CDMO delivering unparalleled service to our pharma and biotech http://www.streetinsider.com/Press+Releases/Catalent+Announces+New+Board+Appointments/24376664.html Thu, 20 Feb 2025 09:00:00 -0400 A.00556501 A.07261051 A.17530805 A.18872811 A.21426713 A.21752794 A.27886773 A.29465233 A.30990768 A.31757664 A.50200199 A.50202556 CTLT H1ZN34 O.00000865 O.00222301 O.00222524 O.00384685 O.00412985 O.00573644 O.00647606 O.02041199 O.02048399 O.05063681 O.22555989 O.26772469 O.55342982 http://www.streetinsider.com/Press+Releases/Catalent+Announces+New+Board+Appointments/24376664.html <p class="bwalignc"> <i>Adds three new directors with deep expertise across biopharma and life sciences</i> </p> <p> SOMERSET, N.J.--(BUSINESS WIRE)-- Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings’ ownership. </p><p> Alessandro Maselli, President and CEO, and Board member of Catalent, said “I am excited to work closely with these new Board members as we drive continued growth as an independent CDMO delivering unparalleled service to our pharma and biotech http://www.streetinsider.com/Press+Releases/Catalent+Announces+New+Board+Appointments/24376664.html Thu, 20 Feb 2025 09:00:00 -0400 A.00556501 A.07261051 A.17530805 A.18872811 A.21426713 A.21752794 A.27886773 A.29465233 A.30990768 A.31757664 A.50200199 A.50202556 CTLT H1ZN34 O.00000865 O.00222301 O.00222524 O.00384685 O.00412985 O.00573644 O.00647606 O.02041199 O.02048399 O.05063681 O.22555989 O.26772469 O.55342982 http://www.streetinsider.com/Press+Releases/Catalent+Announces+New+Board+Appointments/24376664.html <p class="bwalignc"> <i>Adds three new directors with deep expertise across biopharma and life sciences</i> </p> <p> SOMERSET, N.J.--(BUSINESS WIRE)-- Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings’ ownership. </p><p> Alessandro Maselli, President and CEO, and Board member of Catalent, said “I am excited to work closely with these new Board members as we drive continued growth as an independent CDMO delivering unparalleled service to our pharma and biotech http://www.streetinsider.com/Press+Releases/Catalent+Announces+New+Board+Appointments/24376664.html Thu, 20 Feb 2025 09:00:00 -0400 A.00556501 A.07261051 A.17530805 A.18872811 A.21426713 A.21752794 A.27886773 A.29465233 A.30990768 A.31757664 A.50200199 A.50202556 CTLT H1ZN34 O.00000865 O.00222301 O.00222524 O.00384685 O.00412985 O.00573644 O.00647606 O.02041199 O.02048399 O.05063681 O.22555989 O.26772469 O.55342982 http://www.streetinsider.com/Press+Releases/Catalent+Announces+New+Board+Appointments/24376664.html <p class="bwalignc"> <i>Adds three new directors with deep expertise across biopharma and life sciences</i> </p> <p> SOMERSET, N.J.--(BUSINESS WIRE)-- Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings’ ownership. </p><p> Alessandro Maselli, President and CEO, and Board member of Catalent, said “I am excited to work closely with these new Board members as we drive continued growth as an independent CDMO delivering unparalleled service to our pharma and biotech http://www.streetinsider.com/Press+Releases/Catalent+Announces+New+Board+Appointments/24376664.html Thu, 20 Feb 2025 09:00:00 -0400 A.00556501 A.07261051 A.17530805 A.18872811 A.21426713 A.21752794 A.27886773 A.29465233 A.30990768 A.31757664 A.50200199 A.50202556 CTLT H1ZN34 O.00000865 O.00222301 O.00222524 O.00384685 O.00412985 O.00573644 O.00647606 O.02041199 O.02048399 O.05063681 O.22555989 O.26772469 O.55342982 http://www.streetinsider.com/Press+Releases/Catalent+Announces+New+Board+Appointments/24376664.html <p class="bwalignc"> <i>Adds three new directors with deep expertise across biopharma and life sciences</i> </p> <p> SOMERSET, N.J.--(BUSINESS WIRE)-- Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings’ ownership. </p><p> Alessandro Maselli, President and CEO, and Board member of Catalent, said “I am excited to work closely with these new Board members as we drive continued growth as an independent CDMO delivering unparalleled service to our pharma and biotech http://www.streetinsider.com/Press+Releases/Catalent+Announces+New+Board+Appointments/24376664.html Thu, 20 Feb 2025 09:00:00 -0400 A.00556501 A.07261051 A.17530805 A.18872811 A.21426713 A.21752794 A.27886773 A.29465233 A.30990768 A.31757664 A.50200199 A.50202556 CTLT H1ZN34 O.00000865 O.00222301 O.00222524 O.00384685 O.00412985 O.00573644 O.00647606 O.02041199 O.02048399 O.05063681 O.22555989 O.26772469 O.55342982 http://www.streetinsider.com/Press+Releases/Catalent+Announces+New+Board+Appointments/24376664.html <p class="bwalignc"> <i>Adds three new directors with deep expertise across biopharma and life sciences</i> </p> <p> SOMERSET, N.J.--(BUSINESS WIRE)-- Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings’ ownership. </p><p> Alessandro Maselli, President and CEO, and Board member of Catalent, said “I am excited to work closely with these new Board members as we drive continued growth as an independent CDMO delivering unparalleled service to our pharma and biotech http://www.streetinsider.com/Press+Releases/Catalent+Announces+New+Board+Appointments/24376664.html Thu, 20 Feb 2025 09:00:00 -0400 A.00556501 A.07261051 A.17530805 A.18872811 A.21426713 A.21752794 A.27886773 A.29465233 A.30990768 A.31757664 A.50200199 A.50202556 CTLT H1ZN34 O.00000865 O.00222301 O.00222524 O.00384685 O.00412985 O.00573644 O.00647606 O.02041199 O.02048399 O.05063681 O.22555989 O.26772469 O.55342982 http://www.streetinsider.com/Press+Releases/Catalent+Announces+New+Board+Appointments/24376664.html <p class="bwalignc"> <i>Adds three new directors with deep expertise across biopharma and life sciences</i> </p> <p> SOMERSET, N.J.--(BUSINESS WIRE)-- Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings’ ownership. </p><p> Alessandro Maselli, President and CEO, and Board member of Catalent, said “I am excited to work closely with these new Board members as we drive continued growth as an independent CDMO delivering unparalleled service to our pharma and biotech http://www.streetinsider.com/Press+Releases/Catalent+Announces+New+Board+Appointments/24376664.html Thu, 20 Feb 2025 09:00:00 -0400 A.00556501 A.07261051 A.17530805 A.18872811 A.21426713 A.21752794 A.27886773 A.29465233 A.30990768 A.31757664 A.50200199 A.50202556 CTLT H1ZN34 O.00000865 O.00222301 O.00222524 O.00384685 O.00412985 O.00573644 O.00647606 O.02041199 O.02048399 O.05063681 O.22555989 O.26772469 O.55342982